Annals of Epidemiology
Volume 19, Issue 6 , Pages 404-409 , June 2009

Determinants of Cutaneous Injection-Related Infection Care at a Supervised Injecting Facility

  • Elisa Lloyd-Smith

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada
    • School of Population and Public Health, University of British Columbia, Vancouver, Canada
    • ,
  • Evan Wood, MD, PhD

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada
    • Department of Medicine, University of British Columbia, Vancouver, Canada
    • ,
  • Ruth Zhang, MSc

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada
    • ,
  • Mark W. Tyndall, MD, ScD

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada
    • School of Population and Public Health, University of British Columbia, Vancouver, Canada
    • ,
  • Julio S. Montaner, MD, FRCPC

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada
    • Department of Medicine, University of British Columbia, Vancouver, Canada
    • ,
  • Thomas Kerr, PhD

      Affiliations

    • Department of Medicine, University of British Columbia, Vancouver, Canada
    • Corresponding Author InformationAddress correspondence to: Thomas Kerr, BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada. Tel: (604) 806-9116. fax: (604) 806-9044.

Received 8 September 2008 ,Accepted 2 March 2009.

References 

  1. White AG. Medical disorders in 200 consecutive admissions. JAMA. 1973;223:1469–1471
  2. Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001;33:35–40
  3. Palepu A, Tyndall MW, Leon H, Muller J, O'Shaughnessy MV, Schechter MT, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001;165:415–420
  4. del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol. 2004;150:1–10
  5. Bergstein JM, Baker EJ, Aprahamian C, Schein M, Wittmann DH. Soft tissue abscesses associated with parenteral drug abuse: presentation, microbiology, and treatment. Am Surg. 1995;61:1105–1108
  6. Biller JA, Murr AH. The importance of etiology on the clinical course of neck abscesses. Otolaryngol Head Neck Surg. 2004;131:338–391
  7. Takahashi TA, Baernstein A, Binswanger IA, Bradley K, Merrill JO. Predictors of hospitalization for injection drug users seeking care for soft tissue infections. J Gen Intern Med. 2007;22:382–388
  8. Harris HW, Young DM. Care of Injection Drug Users With Soft Tissue Infections in San Francisco, California. Arch Surg. 2002;137:1217–1222
  9. Heinzerling KG, Etzioni DA, Hurley B, Holtom P, Bluthenthal RN, Asch SM. Hospital Utilization for Injection Drug Use-Related Soft Tissue Infections in Urban versus Rural Counties in California. J Urban Health. 2006;83:176–181
  10. CDC . Soft tissue infections among injection drug users–San Francisco, California, 1996-2000. MMWR Morb Mortal Wkly Rep. 2001;50:381–384
  11. Bluthenthal RN, Heinzerling KG, Martinez A, Kral A. Police crackdowns, societal cost, and the need for alternative approaches. Int J Drug Policy. 2005;16:137–138
  12. Grau LE, Arevalo S, Catchpool C, Heimer R. Expanding harm reduction services through a wound and abscess clinic. Am J Public Health. 2002;92:1915–1917
  13. Pollack HA, Khoshnood K, Blankenship KM, Altice FL. The impact of needle exchange-based health services on emergency department use. J Gen Intern Med. 2002;17:341–348
  14. Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, et al. Rationale for evaluating North America;s first medically supervised safer injecting facility. Lancet Infect Dis. 2004;4:301–306
  15. Kimber J, Dolan K, van Beek I, Hedrich D, Zurhold H. Drug consumption facilities: an update since 2000. Drug Alcohol Rev. 2003;22:227–233
  16. Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health. 2001;91:46–47
  17. Dolan K, Kimber J, Fry C, Fitzgerald J, McDonald D, Frautmann F. Drug Consumption Facilities in Europe and the Establishment of Supervised Injecting Centres in Australia. Drug Alcohol Rev. 2000;19:337–346
  18. Wright NM, Tompkins CN. Supervised injecting centres. BMJ. 2004;328:100–102
  19. Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh DC, Montaner JS, et al. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct J. 2004;1:9
  20. Kerr T, Tyndall M, Li K, Montaner JS, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005;366:316–318
  21. Wood E, Tyndall M, Li K, Lloyd-Smith E, Small W, Montaner J, et al. Do Supervised Injecting Facilities Attract Higher-Risk Injection Drug Users?. Am J Prev Med. 2005;29:126–130
  22. Wei L, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84:1065–1073
  23. Reid N, Crepeau H. Influence functions for proportional hazard regression. Biometrika. 1985;72:1–9
  24. Palepu A, Strathdee SA, Hogg RS, Anis AH, Rae S, Cornelisse PG, et al. The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health. 1999;76:409–418
  25. Spijkerman IJ, van Ameijden EJ, Mientjes GH, Coutinho RA, van den Hoek A. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol. 1996;49:1149–1154
  26. Topp L, Iversen J, Conroy A, Salmon AM, Maher L. Prevalence and predictors of injecting-related injury and disease among clients of Australia's needle and syringe programs. Aust N Z J Public Health. 2008;32:34–37
  27. Lloyd-Smith E, Kerr T, Hogg RS, Li K, Montaner JS, Wood E. Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduct J. 2005;2:24
  28. Shannon K, Kerr T, Bright V, Gibson K, Tyndall M. Drug sharing with clients as a risk marker for increased violence and sexual and drug-related harms among survival sex workers. AIDS Care. 2008;20:235–241
  29. French MT, McGeary KA, Chitwood DD, McCoy CB. Chronic illicit drug use, health services utilization and the cost of medical care. Soc Sci Med. 2000;50:1703–1713
  30. Wood E, Tyndall MW, Zhang R, Stoltz JA, Montaner JSG, Kerr T. Attendance at supervised injection facilities and use of detoxification services. N Engl J Med. 2006;354:2512–2514
  31. Wood RA, Wood E, Lai C, Tyndall MT, Montaner JSG, Kerr T. Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver's supervised injection facility. Int J Drug Policy. 2008;19:183–188
  32. Wood E, Spittal PM, Kerr T, Small W, Tyndall MW, O'Shaughnessy MV, et al. Requiring help injecting as a risk factor for HIV infection in the Vancouver epidemic: implications for HIV prevention. Can J Public Health. 2003;94:355–359
  33. O'Connell JM, Kerr T, Li K, Tyndall MW, Hogg RS, Montaner JS, et al. Requiring help injecting independently predicts incident HIV infection among injection drug users. J Acquir Immune Defic Syndr. 2005;40:83–88
  34. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:253–263

PII: S1047-2797(09)00078-7

doi: 10.1016/j.annepidem.2009.03.007

Annals of Epidemiology
Volume 19, Issue 6 , Pages 404-409 , June 2009

Article Tools

* Image Usage & Resolution